<SEC-DOCUMENT>0000078003-24-000195.txt : 20241217
<SEC-HEADER>0000078003-24-000195.hdr.sgml : 20241217
<ACCEPTANCE-DATETIME>20241217074710
ACCESSION NUMBER:		0000078003-24-000195
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241217
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241217
DATE AS OF CHANGE:		20241217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		241553672

	BUSINESS ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192
		BUSINESS PHONE:		2127332323

	MAIL ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pfe-20241217.htm
<DESCRIPTION>PFIZER 8-K DECEMBER 17, 2024
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dc94d1af-f401-4112-925c-872ecd3520f4,g:bea4e81e-da63-4a2c-9c2d-7d985cd27d5f,d:5ee82098d79c43a29975ac87ec1bd580-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20241217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pfe-20241217</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-27">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pfe-20241217.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-17</xbrli:startDate><xbrli:endDate>2024-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-17</xbrli:startDate><xbrli:endDate>2024-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-17</xbrli:startDate><xbrli:endDate>2024-12-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ee82098d79c43a29975ac87ec1bd580_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-2">8-K</ix:nonNumeric></ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">December 17, 2024</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-5">PFIZER INC</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.064%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.892%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-7">1-3619</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">13-5315170</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.75pt"><tr><td style="width:1.0pt"/><td style="width:91.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:55.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">66 Hudson Boulevard East</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">10001-2192</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">New York</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">212</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">733-2323</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.005%"><tr><td style="width:1.0%"/><td style="width:40.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.791%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.746%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-19">Common Stock, $.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-20">PFE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-21">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-22">1.000% Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-23">PFE27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-24">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company &#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-25">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:11.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.853%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 7.01. &#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On December 17, 2024, Pfizer Inc. issued a press release that provided its full-year 2025 guidance and reaffirmed its full-year 2024 financial guidance. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. </span></div><div style="padding-left:2.25pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information furnished pursuant to this &#8220;Item 7.01 &#8211; Regulation FD Disclosure&#8221;, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:11.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.853%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01.           Financial Statements and Exhibits. </span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit Description</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-12172024xexh99.htm">Press Release of Pfizer Inc. dated December 17, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-12172024xexh99.htm">2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="15" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i5ee82098d79c43a29975ac87ec1bd580_7"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PFIZER INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Corporate Secretary</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Governance Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: December 17, 2024</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pfe-12172024xexh99.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6ca98b38d2a64fb38568446f46dcf8a8_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  </font><img alt="pfizerlogoa.jpg" src="pfizerlogoa.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"></div><div style="margin-bottom:8pt;padding-left:5.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.17pt;padding-right:104.37pt"><font><br></font></div><div style="padding-left:0.87pt;padding-right:104.37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For Immediate Release </font></div><div style="padding-left:0.87pt;padding-right:104.37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 17, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-left:100.87pt;padding-right:-2.63pt;text-indent:-90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Media Contact&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">PfizerMediaRelations&#64;Pfizer.com</font></div><div style="margin-bottom:0.2pt;padding-left:100.87pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;+1 (212) 733-1226</font></div><div style="padding-right:3.37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;</font></div><div style="padding-left:10.87pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investor Contact&#58;     </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">IR&#64;Pfizer.com</font></div><div style="padding-left:105.37pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">+1 (212) 733-4848</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> </font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance</font></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.61pt">Full-Year 2025 Revenue Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Range of $61.0 to $64.0 Billion </font></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.61pt">Full-Year 2025 Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Diluted EPS Guidance Range of $2.80 to $3.00</font></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.61pt">Expect Full-Year 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Diluted EPS Operational</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.61pt">Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in 2025 from Ongoing Cost Realignment Program</font></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.61pt">First Phase of Manufacturing Optimization Program On Track to Deliver Initial Net Cost Savings in the Latter Part of 2025, Toward Goal of Improving Gross Margin Performance</font></div><div style="margin-bottom:12pt;margin-top:21pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">NEW YORK, December 17, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8212; Pfizer Inc. (NYSE&#58;PFE) today provided its full-year 2025 guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and reaffirmed its October 29, 2024 full-year 2024 guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">. The accompanying presentation can be found at www.pfizer.com&#47;investors. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Full-Year 2025 Revenue Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024. Pfizer expects fu</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">ll-year 2025 operational</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:150%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%"> revenue growth, year-over-year, in a range of approximately flat to 5% from the midpoint of 2024 baseline guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:150%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">, which excludes 2024 non-recurring items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:150%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">2025 Re</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">venue guidance takes into consideration the anticipated net unfavorable impact to revenue of approximately</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%"> $1 billion, year-over-year, </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">related to the Inflation Reduction Act (IRA) Part D Redesign changes that take effect in 2025. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:150%">The IRA makes significant changes to the Medicare Part D benefit design, which will impact Pfizer revenue in 2025, including&#58; an expected favorable impact from the $2,000 annual out-of-pocket cap and new Prescription Payment Plan, more than offset by an expected unfavorable impact from the sunsetting of the Coverage Gap Discount Program and the addition of new manufacturer discounts in the initial and catastrophic coverage phases.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 1 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Full-Year 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> SI&#38;A and Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> R&#38;D Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer anticipates full-year 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> SI&#38;A expenses to be in the range of $13.3 to $14.3 billion and full-year 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> R&#38;D expenses to be in the range of $10.7 to $11.7 billion. Consequently, total 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> SI&#38;A and R&#38;D expenses are expected to be in the range of $24.0 to $26.0 billion. This range reflects approximately $4.0 billion in net operating expense savings from our cost realignment program achieved through the end of 2024 and anticipates an additional $500 million of savings in 2025.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Full-Year 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> Diluted EPS Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer anticipates full-year 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS to be in a range of $2.80 to $3.00, reflecting expected operational</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> growth of 10% to 18%, year-over-year, from the midpoint of our 2024 baseline guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, which excludes 2024 non-recurring items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">. 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS guidance primarily reflects our expected revenues, anticipated operating margin improvement from continued cost management, and the non-recurrence of the following items that are expected to favorably impact 2024 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS by approximately $0.30&#58; </font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">During 2024, Pfizer recognized Paxlovid revenue of $1.2 billion from two one-time items&#58; $771 million from a U.S. Government revenue credit true-up and $442 million from the fulfillment of our obligated delivery of one million treatment courses to the U.S. Strategic National Stockpile&#59; </font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">With the reduction of our Haleon ownership percentage in the fourth quarter of 2024, Haleon equity method income will no longer be included in Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> earnings in 2025&#59; and</font></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">Our 2024 tax rate on adjusted income was favorably impacted by the timing of Pillar 2 and, to a lesser extent, audit settlements.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 2 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">A comparison of Pfizer&#8217;s 2024 Financial Guidance to its 2025 Financial Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> is presented below.</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.896%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024 Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(as of December 17, 2024)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024 Non-Recurring Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024 Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Baseline excluding non-recurring items)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025 Financial Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Revenues ($ in billions)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$61.0 &#8211; $64.0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:1.38pt;padding-right:1.38pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#126;($1.2)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$59.8 &#8211; $62.8</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$61.0 &#8211; $64.0</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> SI&#38;A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($ in billions)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$13.8 &#8211; $14.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$13.3 &#8211; $14.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> R&#38;D Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($ in billions)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$11.0 &#8211; $12.0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$10.7 &#8211; $11.7</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Tax Rate on Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Income</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#126;13%</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">&#126;15%</font></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Diluted EPS</font></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$2.75 &#8211; $2.95</font></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#126;($0.30)</font></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$2.45 &#8211; $2.65</font></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$2.80 &#8211; $3.00</font></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer&#8217;s expected 2025 operational</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> revenue and Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS growth, year-over-year, versus its 2024 baseline guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> midpoint is presented below.</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:25.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> (Baseline excluding non-recurring items)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025 Financial Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operational Growth</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Revenues ($ in billions)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$59.8 &#8211; $62.8       </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:133%">(midpoint $61.3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$61.0 &#8211; $64.0</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#126; flat to &#126; 5%</font></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Diluted EPS</font></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">$2.45 &#8211; $2.65         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:133%">(midpoint $2.55)</font></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">$2.80 &#8211; $3.00</font></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#126; 10% to &#126; 18%</font></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Financial guidance for Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS is calculated using approximately 5.74 billion weighted average shares outstanding, and assumes no share repurchases in 2024 or 2025.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Executive Commentary</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, stated&#58; &#8220;Pfizer is in a strong position to continue making a positive impact for patients and delivering on our financial commitments in 2025. Our team will build on a year of disciplined execution in 2024 and our product portfolio remains strong.</font></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8220;We also expect to continue improving our operating margins with focused financial discipline. We&#8217;ve been successful in delivering on our goal of $4 billion in net operating expense savings through 2024 from our cost realignment program, with an additional $500 million still expected to come in 2025. Additionally, in support of our ongoing efforts to improve gross margin </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 3 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">performance, we will work to make additional progress with our Manufacturing Optimization Program in the coming year.</font></div><div style="margin-bottom:18pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8220;As we look forward, we are confident in our future. With our clear strategic roadmap, a robust pipeline of potential innovative medicines and vaccines and a talented team laser-focused on execution, we believe we are on course to deliver significant shareholder value.&#8221; </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer intends to provide additional commentary in an analyst webcast scheduled for 8&#58;30 a.m. EST, Tuesday, December 17, 2024&#59; details can be found at www.investors.pfizer.com.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 4 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Pfizer does not provide guidance for U.S. generally accepted accounting principles (GAAP) Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP Reported results for the guidance period.</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Financial guidance for full-year 2025 reflects the following&#58;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.5pt">Does not assume the completion of any business development transactions not completed as of December 16, 2024.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.5pt">Reflects an anticipated negative revenue impact of approximately $0.6 billion due to recent and expected generic and biosimilar competition for certain products that have recently lost patent or regulatory protection or that are anticipated to lose patent or regulatory protection.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.5pt">Exchange rates assumed are actual rates at mid-November 2024.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.5pt">Guidance for Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.74 billion shares, and assumes no share repurchases in 2025.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Our reaffirmed financial guidance for full-year 2024 reflects assumptions that are consistent with those outlined in Note (1) within Pfizer&#8217;s Q3-24 Earnings Release.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Adjusted income and Adjusted diluted earnings per share (EPS) are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and U.S. GAAP diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations, and certain significant items. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Non-GAAP Financial Measure&#58; Adjusted Income </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer&#8217;s 2023 Annual Report on Form 10-K for a definition of each component of Adjusted income as well as other relevant information. </font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">References to operational variances in this press release pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although exchange rate changes are part of Pfizer&#8217;s business, they are not within Pfizer&#8217;s control and because they can mask positive or negative trends in the business, Pfizer believes presenting operational variances excluding these foreign exchange changes provides useful</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">information to evaluate Pfizer&#8217;s results.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 5 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Pfizer reaffirms 2024 Guidance (last updated on October 29, 2024) as of the publication of this December 17, 2024 press release. Within this press release and other related materials, all references to Pfizer&#8217;s 2024 baseline guidance indicates our 2024 Guidance excluding 2024 non-recurring items. Our 2024 baseline Revenue guidance range excludes $1.2 billion in non-recurring 2024 Paxlovid revenues, and our baseline Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> diluted EPS guidance range excludes an anticipated favorable impact in 2024 of approximately $0.30 from non-recurring items, as outlined under the &#8216;Full-Year 2025 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Diluted EPS Guidance&#8217; section of this press release.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Expected operational growth percentage, on a year-over-year basis, represents lower and upper end of the 2025 guidance range versus the midpoint of the 2024 baseline guidance range.</font></div><div style="margin-bottom:24pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(6)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Revenues is defined as revenues in accordance with U.S. GAAP.&#160;Reported net income and its components are defined as net income attributable to Pfizer Inc. common shareholders and its components in accordance with U.S. GAAP. Reported diluted EPS is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.</font></div><div style="margin-bottom:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DISCLOSURE NOTICE</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in this press release is as of December 17, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release or the webcast as the result of new information or future events or developments.</font></div><div style="margin-bottom:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release and the webcast contain or may contain forward-looking information about, among other topics, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our anticipated operating and financial performance, including financial guidance and projections&#59; reorganizations&#59; business plans, strategy, goals and prospects&#59; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, including demand, market size and utilization rates and growth, performance, timing of exclusivity and potential benefits&#59; strategic reviews&#59; capital allocation objectives&#59; an enterprise-wide cost realignment program, which we launched in October 2023 (including anticipated costs, savings and potential benefits)&#59; a Manufacturing Optimization Program to reduce our cost of goods sold, which we announced in May 2024 (including anticipated costs, savings and potential benefits)&#59; dividends and share repurchases&#59; plans for and prospects of our acquisitions, dispositions and other business development activities, including our December 2023 acquisition of Seagen, and our ability to successfully capitalize on growth opportunities and prospects&#59; manufacturing and product supply&#59; our ongoing efforts to respond to COVID-19, including our plans and expectations regarding Comirnaty and our oral COVID-19 treatment (Paxlovid)&#59; our expectations regarding the impact of COVID-19 on our business, operations and financial results&#59; and our Environmental, Social and Governance (ESG) priorities, strategies and goals. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions and we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;potential,&#8221; &#8220;hope&#8221; and other words and terms of similar meaning. Pfizer&#8217;s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following&#58;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations, and Business Development&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the outcome of research and development (R&#38;D) activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and&#47;or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and&#47;or regulatory approval and&#47;or launch dates&#59; the possibility of </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 6 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data&#59; risks associated with preliminary, early stage or interim data&#59; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review&#47;publication process, in the scientific community generally, and by regulatory authorities&#59; whether and when additional data from our pipeline programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations&#59; and uncertainties regarding the future development of our product candidates, including whether or when our product candidates will advance to future studies or phases of development or whether or when regulatory applications may be filed for any of our product candidates&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully address comments received from regulatory authorities such as the U.S. Food and Drug Administration or the European Medicines Agency, or obtain approval for new products and indications from regulators on a timely basis or at all&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and&#47;or other matters, including decisions relating to emerging developments regarding potential product impurities&#59; uncertainties regarding the ability to obtain, and the scope of, recommendations by technical or advisory committees&#59; and the timing of, and ability to obtain, pricing approvals and product launches, all of which could impact the availability or commercial potential of our products and product candidates&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the conduct or outcome of post-approval clinical trials, pharmacovigilance or Risk Evaluation and Mitigation Strategies, which could impact marketing approval, product labeling, and&#47;or availability or commercial potential&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success and impact of external business development activities, such as the December 2023 acquisition of Seagen, including the ability to identify and execute on potential business development opportunities&#59; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all&#59; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all&#59; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which has in the past and could in the future result in increased leverage and&#47;or a downgrade of our credit ratings and could limit our ability to obtain future financing&#59; challenges integrating the businesses and operations&#59; disruption to business and operations relationships&#59; risks related to growing revenues for certain acquired or partnered products&#59; significant transaction costs&#59; and unknown liabilities&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully market both new and existing products, including biosimilars&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">difficulties or delays in manufacturing, sales or marketing&#59; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on&#59; and legal or regulatory actions&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&#38;D and clinical trials&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to our efforts to continue to develop and commercialize Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, as well as challenges related to their manufacturing, supply and distribution, including, among others, the risk that as the market for COVID-19 products continues to become more endemic and seasonal, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, or may no longer exist, which has and may continue to lead to reduced revenues, excess inventory on-hand and&#47;or in the channel which, for Paxlovid and Comirnaty, resulted in significant inventory write-offs in 2023 and could continue to result in inventory write-offs, or other unanticipated charges&#59; risks related to our ability to develop and commercialize variant adapted vaccines&#59; uncertainties related to the public&#8217;s adherence to vaccines, boosters, treatments or combinations&#59; risks related to our ability to accurately predict or achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments&#59; and potential third-party royalties or other claims related to Comirnaty or Paxlovid&#59;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 7 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interest rate and foreign currency exchange rate fluctuations, including the impact of currency devaluations and monetary policy actions in countries experiencing high inflation or deflation rates&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to our JVs and other third-party business arrangements, including modifications or disputes related to supply agreements or other contracts with customers including governments or other payors&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation or interest rate fluctuations, and recent and possible future changes in global financial markets&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions and&#47;or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of disruptions related to climate change and natural disasters&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the resulting economic or other consequences&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, such as our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines, and our voluntary withdrawal of all lots of Oxbryta in all markets where it is approved and any potential regulatory or other impact on other sickle cell disease assets&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trade buying patterns&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, including any potential future phases, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences&#59;</font></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully achieve our climate goals and progress our environmental sustainability and other ESG priorities&#59;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any U.S. healthcare reform or legislation or any significant spending reduction or cost control efforts affecting Medicare, Medicaid or other publicly funded or subsidized health programs, including the Inflation Reduction Act of 2022, or changes in the tax treatment of employer-sponsored health insurance that may be implemented&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal or state legislation or regulatory action and&#47;or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising&#59; limitations on interactions with healthcare professionals and other industry stakeholders&#59; as well as pricing pressures for our products as a result of highly competitive biopharmaceutical markets&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medical </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 8 -</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulation, environmental protections, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to legal proceedings and actual or alleged environmental contamination&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of tax related litigation and investigations&#59;</font></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">governmental laws and regulations affecting our operations, including, without limitation, the Inflation Reduction Act of 2022, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024, and potential changes to existing tax laws, tariffs, or changes to other laws and regulations proposed by the U.S. presidential administration&#59;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Intellectual Property, Technology and Security&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services)&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack, which may include those using adversarial artificial intelligence techniques, or other malfeasance by, but not limited to, nation states, employees, business partners or others&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and challenges related to the use of software and services that include artificial intelligence-based functionality and other emerging technologies&#59;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all&#59; and</font></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks to our products, patents and other intellectual property, such as&#58; (i) claims of invalidity that could result in patent revocation&#59; (ii) claims of patent infringement, including asserted and&#47;or unasserted intellectual property claims&#59; (iii) claims we may assert against intellectual property rights held by third parties&#59; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights&#59; or (v) any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our subsequent reports on Form 10-Q, in each case including in the sections thereof captioned &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; and &#8220;Item 1A. Risk Factors,&#8221; and in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.pfizer.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - 9 -</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pfe-20241217.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dc94d1af-f401-4112-925c-872ecd3520f4,g:bea4e81e-da63-4a2c-9c2d-7d985cd27d5f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20241217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20241217">
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20241217_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20241217_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20241217_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pfe_NotesDue20271.000Member" abstract="true" name="NotesDue20271.000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>pfe-20241217_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dc94d1af-f401-4112-925c-872ecd3520f4,g:bea4e81e-da63-4a2c-9c2d-7d985cd27d5f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20241217.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9d67b8f7-48cf-4bb9-ad45-3d897640c57f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntitiesTable_9d67b8f7-48cf-4bb9-ad45-3d897640c57f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10acf45c-43dc-4143-880f-12fc32a1b303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_9d67b8f7-48cf-4bb9-ad45-3d897640c57f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10acf45c-43dc-4143-880f-12fc32a1b303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_10acf45c-43dc-4143-880f-12fc32a1b303_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10acf45c-43dc-4143-880f-12fc32a1b303" xlink:to="loc_us-gaap_ClassOfStockDomain_10acf45c-43dc-4143-880f-12fc32a1b303_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10acf45c-43dc-4143-880f-12fc32a1b303" xlink:to="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a1c63fbd-eed6-444d-9554-a661ebdb283a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:to="loc_us-gaap_CommonStockMember_a1c63fbd-eed6-444d-9554-a661ebdb283a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_34376f4f-f3a5-4e69-bfb7-dbfd5d1eeef2" xlink:href="pfe-20241217.xsd#pfe_NotesDue20271.000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:to="loc_pfe_NotesDue20271.000Member_34376f4f-f3a5-4e69-bfb7-dbfd5d1eeef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_96319ff5-68ec-4d10-96d8-203fb34635a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_Security12bTitle_96319ff5-68ec-4d10-96d8-203fb34635a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_52a3629f-2cc9-4cd4-9775-dd119a910857" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_DocumentType_52a3629f-2cc9-4cd4-9775-dd119a910857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_50390acb-4811-4de6-8a01-907a03159ab4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_DocumentPeriodEndDate_50390acb-4811-4de6-8a01-907a03159ab4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c0450cdb-6572-435b-a3ef-d1c4682aaa03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityRegistrantName_c0450cdb-6572-435b-a3ef-d1c4682aaa03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2b0eec0f-7c73-40b4-a749-d96bd06ab0b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2b0eec0f-7c73-40b4-a749-d96bd06ab0b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a6806651-1693-4625-8018-e504384df1bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityFileNumber_a6806651-1693-4625-8018-e504384df1bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_84d5cb49-0a62-434c-87ac-3c74004b5012" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityTaxIdentificationNumber_84d5cb49-0a62-434c-87ac-3c74004b5012" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f4c8e27f-720d-4c85-9a28-4705e164a84d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressAddressLine1_f4c8e27f-720d-4c85-9a28-4705e164a84d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ae65acbd-1726-415d-bd24-9ed4a5449dc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressCityOrTown_ae65acbd-1726-415d-bd24-9ed4a5449dc1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_12b3c3ad-f1cc-48f9-89a6-5635864a2d0b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressStateOrProvince_12b3c3ad-f1cc-48f9-89a6-5635864a2d0b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8b572ddd-2bb2-44bd-ac50-2a9fed2315dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressPostalZipCode_8b572ddd-2bb2-44bd-ac50-2a9fed2315dc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3f37c508-128c-43ad-b9d5-f8e45b09f5e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_CityAreaCode_3f37c508-128c-43ad-b9d5-f8e45b09f5e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_966aa98f-2c99-4228-a4e1-1cc467cbf42e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_LocalPhoneNumber_966aa98f-2c99-4228-a4e1-1cc467cbf42e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8fa11197-6e38-4f34-9fd5-d63964b12a1c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_WrittenCommunications_8fa11197-6e38-4f34-9fd5-d63964b12a1c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fe3e6db6-00ff-4568-839d-88e1fba1d4f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_SolicitingMaterial_fe3e6db6-00ff-4568-839d-88e1fba1d4f2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_59852eeb-1176-41ec-93d1-adac1d99e47d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_PreCommencementTenderOffer_59852eeb-1176-41ec-93d1-adac1d99e47d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d4022fa6-64c4-4ea5-aadd-eddbf35977a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d4022fa6-64c4-4ea5-aadd-eddbf35977a5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2b46c2b0-c63c-410f-b398-92e053460643" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityEmergingGrowthCompany_2b46c2b0-c63c-410f-b398-92e053460643" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_96d7bc4a-5de6-4f6c-966c-4d8629af919c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_AmendmentFlag_96d7bc4a-5de6-4f6c-966c-4d8629af919c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_38c8d47c-c49a-4fef-aa56-c55a9165dce9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityCentralIndexKey_38c8d47c-c49a-4fef-aa56-c55a9165dce9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_371c3635-0542-42dd-8a66-a7c911feffae" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_TradingSymbol_371c3635-0542-42dd-8a66-a7c911feffae" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_347f0b36-01b5-4e65-856b-4376e6053f31" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_SecurityExchangeName_347f0b36-01b5-4e65-856b-4376e6053f31" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pfe-20241217_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dc94d1af-f401-4112-925c-872ecd3520f4,g:bea4e81e-da63-4a2c-9c2d-7d985cd27d5f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ClassOfStockDomain_119e8f58-68cb-4ce1-ab81-925c9216825c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c0a75cbf-4c01-483e-841c-5ebebc5a443d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_435f4b72-b558-4fdc-a41c-3a590c0769e7_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1f3a72fc-d860-4d27-859a-7b87b4022efa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20271.000Member_47b39e0c-41bd-4aed-98d5-837fe59fc4c9_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member" xlink:href="pfe-20241217.xsd#pfe_NotesDue20271.000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member" xlink:to="lab_pfe_NotesDue20271.000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_79e72e5f-a117-4f2e-b4c9-b7053cb09763_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4a09fb89-72a5-43b3-ba6e-4800040ddde3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_763ef332-63e4-464f-b314-7b73599052a4_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b3a3aff3-9087-4855-82bd-9d13fde86f6b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4330acaf-f569-420b-ade2-68d256a39e21_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b2e8de74-9a49-4730-a773-848582f204c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b49a0ff8-b1bf-4b13-a58c-6ada38a580a0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5b2b2a1e-d14f-4f17-aa08-af45fb0b8683_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d8da8f12-7236-4950-b808-4efb8c87ec84_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_add66f02-01f3-4a7c-a957-eba0deb6c310_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_8c9c482b-bd48-4c4e-bb0c-a51bc5044009_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7b326d3b-3501-4968-b2b8-0a831404dced_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0dbeed47-ccf0-4c9c-8b98-0c54597d76c7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e222f17b-8890-4580-bf27-4368def03b3b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7f8d0ded-d177-4536-a041-5eb0e86a43fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b15def6d-c32f-4cc7-8258-d09426263e36_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fb6b3bbc-a39c-46d5-960d-c3bca8ed9a1c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a7271184-e03f-4b44-92db-09b5d4261ed2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4e5a9055-8c04-43a0-b373-40d5e6c24f06_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4267c114-69c8-42ed-bc38-28a60fae40e9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_02b08952-a075-4aca-8960-cf520ede72f8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b8f0457a-d784-48a6-92d2-74202680ea0f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_6ae698f5-828a-4815-a96f-c95c90e6f23c_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_700e228f-60aa-4c64-bf4c-ff62033ab142_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pfe-20241217_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:dc94d1af-f401-4112-925c-872ecd3520f4,g:bea4e81e-da63-4a2c-9c2d-7d985cd27d5f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20241217.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aca2cd06-dc37-45ee-8542-d13ba8d45a0f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9d67b8f7-48cf-4bb9-ad45-3d897640c57f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aca2cd06-dc37-45ee-8542-d13ba8d45a0f" xlink:to="loc_dei_EntitiesTable_9d67b8f7-48cf-4bb9-ad45-3d897640c57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10acf45c-43dc-4143-880f-12fc32a1b303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9d67b8f7-48cf-4bb9-ad45-3d897640c57f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10acf45c-43dc-4143-880f-12fc32a1b303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10acf45c-43dc-4143-880f-12fc32a1b303" xlink:to="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a1c63fbd-eed6-444d-9554-a661ebdb283a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:to="loc_us-gaap_CommonStockMember_a1c63fbd-eed6-444d-9554-a661ebdb283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_34376f4f-f3a5-4e69-bfb7-dbfd5d1eeef2" xlink:href="pfe-20241217.xsd#pfe_NotesDue20271.000Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_271dfc89-d160-4cf7-acf8-57f5d62537b9" xlink:to="loc_pfe_NotesDue20271.000Member_34376f4f-f3a5-4e69-bfb7-dbfd5d1eeef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9d67b8f7-48cf-4bb9-ad45-3d897640c57f" xlink:to="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_96319ff5-68ec-4d10-96d8-203fb34635a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_Security12bTitle_96319ff5-68ec-4d10-96d8-203fb34635a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_52a3629f-2cc9-4cd4-9775-dd119a910857" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_DocumentType_52a3629f-2cc9-4cd4-9775-dd119a910857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_50390acb-4811-4de6-8a01-907a03159ab4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_DocumentPeriodEndDate_50390acb-4811-4de6-8a01-907a03159ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c0450cdb-6572-435b-a3ef-d1c4682aaa03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityRegistrantName_c0450cdb-6572-435b-a3ef-d1c4682aaa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2b0eec0f-7c73-40b4-a749-d96bd06ab0b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2b0eec0f-7c73-40b4-a749-d96bd06ab0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a6806651-1693-4625-8018-e504384df1bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityFileNumber_a6806651-1693-4625-8018-e504384df1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_84d5cb49-0a62-434c-87ac-3c74004b5012" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityTaxIdentificationNumber_84d5cb49-0a62-434c-87ac-3c74004b5012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f4c8e27f-720d-4c85-9a28-4705e164a84d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressAddressLine1_f4c8e27f-720d-4c85-9a28-4705e164a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ae65acbd-1726-415d-bd24-9ed4a5449dc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressCityOrTown_ae65acbd-1726-415d-bd24-9ed4a5449dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_12b3c3ad-f1cc-48f9-89a6-5635864a2d0b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressStateOrProvince_12b3c3ad-f1cc-48f9-89a6-5635864a2d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8b572ddd-2bb2-44bd-ac50-2a9fed2315dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityAddressPostalZipCode_8b572ddd-2bb2-44bd-ac50-2a9fed2315dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3f37c508-128c-43ad-b9d5-f8e45b09f5e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_CityAreaCode_3f37c508-128c-43ad-b9d5-f8e45b09f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_966aa98f-2c99-4228-a4e1-1cc467cbf42e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_LocalPhoneNumber_966aa98f-2c99-4228-a4e1-1cc467cbf42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8fa11197-6e38-4f34-9fd5-d63964b12a1c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_WrittenCommunications_8fa11197-6e38-4f34-9fd5-d63964b12a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fe3e6db6-00ff-4568-839d-88e1fba1d4f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_SolicitingMaterial_fe3e6db6-00ff-4568-839d-88e1fba1d4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_59852eeb-1176-41ec-93d1-adac1d99e47d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_PreCommencementTenderOffer_59852eeb-1176-41ec-93d1-adac1d99e47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d4022fa6-64c4-4ea5-aadd-eddbf35977a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d4022fa6-64c4-4ea5-aadd-eddbf35977a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2b46c2b0-c63c-410f-b398-92e053460643" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityEmergingGrowthCompany_2b46c2b0-c63c-410f-b398-92e053460643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_96d7bc4a-5de6-4f6c-966c-4d8629af919c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_AmendmentFlag_96d7bc4a-5de6-4f6c-966c-4d8629af919c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_38c8d47c-c49a-4fef-aa56-c55a9165dce9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_EntityCentralIndexKey_38c8d47c-c49a-4fef-aa56-c55a9165dce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_371c3635-0542-42dd-8a66-a7c911feffae" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_TradingSymbol_371c3635-0542-42dd-8a66-a7c911feffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_347f0b36-01b5-4e65-856b-4376e6053f31" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d4147ebe-fe4f-4744-baa5-071fdb888962" xlink:to="loc_dei_SecurityExchangeName_347f0b36-01b5-4e65-856b-4376e6053f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pfizerlogoa.jpg
<TEXT>
begin 644 pfizerlogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"B17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)O<V5N+"!0
M96YN>2!3+@   >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\%BH?%3?W,Q**FFM;BW8K<021,.H=",5#72FGJCE::T84444Q!1110 4444
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MEC*?/3^:["T445Q'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=-*HW[K/9****^(.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M75VV;JYFG/K)(6_G4%%>C"C2I_!%+T1YLZU6I\<F_5A1116ID%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** .T^%VG&\\7BX(REG$TASZGY1_,_E7M5>?\
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M]_$!.NK1/_O6L?\ 05B^%<:MI1^]_P"0_;Q/L&BOD5?VA/'PZWMH?K:K2_\
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M'Y5\S>+?'GB#QK?&XUR^>1,YCMD.V*,>@7^IYKG*^GPG"M-1YL3*[[+;[_\
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MAQM%%%??G*=K\']6_L?XL:%.6PDUQ]F;W\P%!^I%?:E?!?A:0Q>,-&D7JE_
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MQP$6]Y7?^7X(QJN\PHHHKWS(*^O_ (%>$!X7^'5O<SQE+[5<74V>H4C]VO\
MWSS]6-?+_@;P_P#\)3XYTG1BK-'=7"B;;U$8^9S_ -\@U]T1QK%$L<:A410J
MJ.@ KXOBK%N,(8:/75^G3\?R.BA'6XZBBBO@#J"BBB@ HHHH **** "BBB@
MHHHH *XGXO\ AQO$_P +]5M(5+7$""Z@ &26C^; 'J5W#\:[:BMJ%:5"K&K'
M>+3^X35U8_/:BO0?C+X%;P3XYF^SQD:9J!:XM#V7)^9/^ D_D17GU?LV'KPQ
M%*-:GLT>>TT[,****W$%%%% !1110 4444 %7=*UG4M#OEO-'O9[*X7I) Y4
M_IU'M5*BE**DK25T![MX._:4U"SV6WC&R%]%P/M=L D@'J5Z-^&*]R\,>//#
M?C"W$F@ZI#._\4#'9*OU0\_TKX7J2"XFM9UFMI7AE0Y5XV*LI]B*^:QO#>$Q
M%Y4O<?EM]W^1M&M);GZ"T5\D>$_C_P"+?#WEP:E(FM6B\%;KB0#VD'/YYKVK
MPK\>O!_B(QPWEPVCW;<>7><)GVD''YXKX[&9%C<+KR\R[K7\-SHC5C(]-HJ.
M"XANH%FMI8YHG&5>-@RGZ$5)7A[&@5\O?M+Z[]M\;6&D1R9CT^UWNH/220Y.
M?^ JOYU]0UY?XM^ _A[Q;KUWK%U?ZC!>7;!I"CJ5!  & 5Z8 KVLEQ6'PF+]
MM7V2=M+ZO_@7,ZD7*-D?(U%?0]W^RW&238>)V4=EFM,_J&'\JQ;O]F+Q#'G[
M'K6GS^@=73^AK[^&?9=/:I]Z?^1R^RGV/$J*]6G_ &<_'<6?+33Y_P#KG=8_
M]" K.G^!'Q!@S_Q)5D_ZYW,9_P#9JZHYI@9;58_>B>278\ZHKMI?@[X_A^]X
M:NB/561OY&JDGPP\;Q_>\,:C^$)/\JV6-PKVJ1^]"Y9=CE**Z4_#GQDIP?#&
MJ_A:N?Z4J_#?QF_W?#&J?C;,*KZUA_YU]Z#E?8YFBNOB^%'CJ;[GAB__ .!(
M%_F:OP?!'X@SXQX?DC_ZZ31K_P"S5$L=A([U8_>A\LNQP-%>I6W[._CV?'F6
MUC;Y_P">MVI_]!S6[8_LPZ_+@ZAK=A;^HC1Y/\*Y9YQE\-ZJ^6OY#]G-]#Q"
MBOI;3/V8-'AP=6UZ\NCW6")8@?SW&NQTGX&^ M)8.NC_ &QQ_%>2M)^G3]*\
MZKQ-@(?!>7HO\[%JC)GR!9V%YJ$PAL+2>ZE/1(8RY_(5Z'X<^ OC77BDES9I
MI5NW)DO'PV/]P9/YXKZST_2=.TJ$1:98VUG&/X8(E0?H*MUXF(XJK2TH04?-
MZ_Y?J:*@NIY%X3_9W\,:(8Y]=>36KI>=L@V0@_[@Z_B37J]K:6]C:I;64$=O
M!&,)'$@55'L!4U%?,8G&8C%2YJTV_P"NVQLHJ.P4445R%!1110 4444 %%%%
M !7@7[3^N!+#1M"C?YI)&NI5![ ;5S^);\J]]KXZ^.>N?VW\5]156S%8!;1.
M?[HRW_CQ-?1\-X?VV/4GM%-_HOS,:SM$\[HHHK]0.,*55+N%499C@ =S25U?
MPRT$^(_B3HNG[=T9N%EE'^PGSM^@K.M4C1IRJ2V2;^X$KNQ]@>!M$7P[X%T?
M2U7:UO:H)!_MD9;]2:WJ**_$ZDW4FYRW;N>BM$%%%%0,**** "BBB@ HHHH
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M#L4?3Y2?QKU6OR;/<1[?,*CZ+3[O^#<[J2M!!1117BF@4444 %%%% !1110
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MU;3M7@\[2KZVO(_[]O*KC]#5NO'<7%V9H%%%%( HHHH **** "BBB@ HHHH
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MWMY+_-F-6I=V04445]88!1110 ])9(\^7(R9Z[6(IWVJX_Y[R?\ ?9J*BBR
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M %(RAE*GH1@TM% '"M\%OA^[%F\.0EB<DF:7G_QZD_X4I\/?^A;A_P"_TO\
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M_O\ 2_\ Q5=W11_:&,_Y^R_\"?\ F'+'L9^AZ#IGAK28]-T2T6TLXR66)22
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M+_\ %5W=%']H8S_G[+_P)_YARQ['"?\ "E/A[_T+</\ W^E_^*H_X4I\/?\
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MU&*V04445QE&3XB\+Z/XLT]+'Q!9K>6R2"58V=E 8 @'Y2.Q-<U_PI3X>_\
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>%_M.Z[]G\/:3HD3X:ZG,\JC^Z@P/U;]*]TKY"^/NN_VQ\5+N!&S%IL:VJ_
M4?,WZL1^%?0\.X?VV/C)[1N_T7XLRJNT3S.BBBOU(X@JUI=A)JFKV=A "9+J
M=(5QZLP']:JUZ5\!-"&L_%6SED3=#I\;W3<< @87_P >(_*N;%UUA\/.J_LI
ML<5=V/K;3;&/3-*M;& 8BMH4B0#T4 #^56:**_%FVW=GHA1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,+7?!'AKQ-DZYHMG=OC E>("0#V<<C\Z\TU[]FCPW>J[Z#J%YIDI
MY59")XQ[8.&_\>KVBBN[#YCB\-_"J->73[GH2X1>Z/E#7/V<_&6F9;3#::M'
MV\F3RW_[Y? _(FO/=8\)>(- D9-9T:]L]O5I8&"GZ-T/X&OO&D95=<, P/4$
M5[]#BK%0TJQ4OP?^7X&3H1Z'Y[T5]P:Q\,_!FN[SJ/AVQ9Y/O2Q1^4Y/KN7!
MKA-7_9I\*7:.=*O=0TZ0_=!<2H/P(R?^^J]RCQ1@YZ5$X_BOP_R,G1ET/EJB
MO;M4_9B\06ZEM)UJPO<?PS(T)/\ Z$/UKC-3^"WC[2D9Y= EN$7^*UD27/T"
MG/Z5[%'-L#6^"JOF[?G8APDNAPE%7KW1-5TS/]HZ9>6F.OGV[QX_,51KT8R4
ME>+N0%%%%, HHHH *ZWX7:&/$7Q-T2P==T7V@2RC_83YS_+'XUR5>[?LPZ'Y
M^O:OK<B96V@6WC8CHSG)Q^"_K7G9IB/JV"J5.MM/5Z(N"O)(^DZ***_'3O"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *^H7D>G:9<WLYVQV\32N3V"C/]*^"M7U&75]9O-1N3F6[G>9R?5B3_ %KZ
MW^.NO#1/A3J"*VV;4"MI'S_>.6_\=!KX\K]!X4P_+1G7?5V^[_ASEKO5(***
M*^R.<*^D_P!F+0?(T+5M=D7FZF6WC/\ LH,G]6'Y5\V5]M_"W0AX=^&>C6)3
M;(;<32C_ &W^8_SQ7R_$^(]G@O9K>3_!:_Y&U%7E<ZZBBBOS0[ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!&17&'4,/0C-85]X%\*:FS-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46800829772080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Dec. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 17,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">66 Hudson Boulevard East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001-2192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">Notes Due 2027, 1.000% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .0]D5D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #D/9%91DC>W^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*$[+ B;U96.G%@8K;.QF;+4UBV-C:R1]^SE9FS*V!]C1TN]/
MGT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2F1-];AY\=(KR,QXA*/VA
MC@AU5=V#0U)&D8()6(2%R&1KM- 1%?EXP1N]X,-G[&:8T8 =.NPI 2\Y,#E-
M#.>Q:^$&F&"$T:7O IJ%.%?_Q,X=8)?DF.R2&H:A'%9S+N_ X6VW?9G7+6R?
M2/4:\Z]D!9T#;MAU\NOJX7'_Q&1=U>N"UP5O]KP6ZT94S?OD^L/O)NR\L0?[
MCXVO@K*%7W<AOP!02P,$%     @ Y#V169E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " #D/9%9EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( .0]D5D9117U-P$
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M'R:/6D;KW$JY]_!*MAQSCG^T_ %02P,$%     @ Y#V1620>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( .0]D5EED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #D/9%91DC>W^\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #D/9%9
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( .0]D5GJ:M<&P@0  /X4   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #D/9%9
MGZ ;\+$"  #B#   #0              @ $&#0  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( .0]D5F7BKL<P    !,"   +              "  >(/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( .0]D5D9117U-P$  "<"   /
M      "  <L0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #D/9%9)!Z;
MHJT   #X 0  &@              @ $O$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #D/9%999!YDAD!  #/ P  $P
M    @ $4$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !>
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pfe-20241217.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="pfe-20241217.htm">pfe-20241217.htm</File>
    <File>pfe-20241217.xsd</File>
    <File>pfe-20241217_def.xml</File>
    <File>pfe-20241217_lab.xml</File>
    <File>pfe-20241217_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pfe-20241217.htm": {
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20241217",
   "dts": {
    "inline": {
     "local": [
      "pfe-20241217.htm"
     ]
    },
    "schema": {
     "local": [
      "pfe-20241217.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20241217_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20241217_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20241217_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://www.pfizer.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pfe-20241217.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pfe-20241217.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "pfe_NotesDue20271.000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pfizer.com/20241217",
     "localname": "NotesDue20271.000Member",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "documentation": "Notes Due 2027, 1.000% [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000078003-24-000195-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-24-000195-xbrl.zip
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M>40V"Q#;^S#/R$EX:J9]F] "<L%Y,0)5S*F.)"P:Z2!5\<%90>V2A9)(K7Y
MS[=Q/#2/0']0%:'55%U:>A0!PXYPB^3:4;67+5DQ?=_22X(38ZM+F[+G\A&*
MV+81=CK &9&5!,W*LK36!_$Y0>;N0M\=ET'K'K.5&K>'=_YMT<>WZD!J49FQ
MN,G8 C(ZB4NB;PG+'!YP?+P%-SI$"=9G!0)1<AB9,/+X["TZQ/[MPJK[XUSG
M.+V:14>FAL(#SRAJ,H\_D^OO:$=$Q84-._J*+'>+0]4?U1I0$#IEG4#9/8X3
M9CKH!V=]6 =)M@ "0397S-$;2,D<+$>(0&K4:[K/42Z/K4HL+V_C]'3?NGB
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MENXG=[5)-;M7L<UV8<8>L4B&&0N,5^3V9H_Q%7)@3,6T)0(8.OF;$S*7:52
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M[S^:1\9Q^K]EE.W: @:K6>U5T;/70N_BNG-)UC=C<I\HM>E2*\8L;& '+0,
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M-I<YV4YG74D)UBHT9NRGU/)F,1CMLP(&-90A9BJUFUGB(%3U-2+8I;=S/%_
MC=WBGO?K,,."?GV"&7IX6#5-K7:&Q,$S71O$?=>DZ7NG44Q5R+$[&?5#_T!L
MDC;PYZ#059;'K)B(Y<LP:)"[(8<W]VKF1;-*WHXV3UARUIQ#EZK?B6GUE?!-
M3;-:H9&>:B7J3.4A^:MNE$E$8W)+_>1[,FCWAPDW(70FMJG43H]K&7B0H/5!
MS&=R;6YCIV<S'OH<*/KS.XS6S.YMRM=3,_U5\W5WELJE=72#914:ZC3UWX@Z
M8$W<A.&9H\H''V](X>5*H:24P@<YG\VP&ZL%^SO4PL+>TOH;DSS 3%?<H<L2
MX=XBVM$.7(QK,-*?$$=MMXPHD.%NR#"A_^&6"!<$ALB & ,T0@=Q>">'&!Z)
M<)N$@BY@'G2A#HNET7*P&C*?[4&H'-Z:M5*)'& Z9>581<SSREP=,XOPF!EN
MAZ4Q%JNO64M@S05:4J#V%"C&6^[;S8#5OV='>2<FKK5B$F:/U<]GJNYX5#%-
M(LK1^J*P:J9(K1E0M'9T:^EYK);%[60881SC>'<XK^T]H@0P+6:I1N$+^ZM#
MT!?,9P[>"!>$*MB3"*9J :[9]BW>X<73G3AU1AHY0?7E3[!S=9,<LGT N$%)
MS&ZY@':@A6C@("-3Q\'3@E@9;QMS:>R*=/_6715I*AW0::1I5KWH2X1K!T1L
MRO+OAL6?7_@@P)=?4A.%*9/48^93S$-;N+;F/G:NPN#&?1/:%Z&?R,4F3]UT
MD_X_C._-J@'3^C&CWS3JP2)3I_X=G0BTP[9^Q<X3%'SE[8**?G1D;+I=8$*!
M5=Y*/-TLPP >CZ>O#>I(M\WM'.K>&U"KWU?+CV^(K$@L+^]+7/X5HOR6^=P,
MYQ%W79^]U2D^R4:DHAOFZD6SPP:)GV;97)R3<RX</Q1)S/2G@R];(,J,2LY
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M0F ,:PHT,8XR8FGFJ&#*.B]'87DO[).!NGTRU^GRP=L@UY]@GC=M[<KV@UO
M+%"I:(B>:)5Q=(#*$R<@X>4E2&VX<^[1Q?"?W=*Y'W7GV0Y.Y3I:,1SM41FJ
M^KRJ^T'V?O^PNBC;^OJPBC#CG@($]/59R 21U*-5RR0:":M]I-IYZNDHFW>/
MB'@BX,=+]'H=R.%U\#8OX,/%C4G7AFJM&&':HA8TB,109@@H*H61,3$_PF;G
MG8A/A/"6*5S'J8;C/'571Q$O)'G*;VXP+H5A;!4\%A9UNIMO9'<WU@4B0B8I
ME5Y1-L9N_#?"/Q'08R1WG;H>3OU5C#4TS?)/-UPV2S(8X!G.+)Q&M(9&$>NX
MP4%3!4Q+AZI'(+XA]!.A/32IZZ2ST4@?XMN/]6EU6<X<:(4>,1*6<4TD4Y'X
MR'$= %$Z):6-@8W'^3;PTZ*\94+7&9O1&/=>X6-]7%=?\C+ #-?M(@@726(!
ME^LF66*LTT3A0MU@Z?%(_7B@'T1_6K2'I'8=N1T-^7'5M*[X;W[>>T/C<6T0
M8R3<>[RL2"Q)%Q0EW-D$D>,",(;Q@-^+_;1P;Y_6#7LF@_:]NFGF50VN%R*2
MR#"P(8R;[H8*UI^W49%D0"I/;5+PV/VE[_.]&VWGB6Z=N@T,!VU\=8_N%<=G
M5;DR_59KYZSI-N&L)9*C'W 2< T0<"V?!9\DW_ 4T@]P?!AQYUD.2N$&GH.V
MNGZO\[:%LKMI=5$NC7TS,\DQQFQ&- CT=TF@ 4A885$+JZ5GW+%AD^_&L#M/
M=G@R-^ =M-UU4A5YP"26\_=XT:]S5\P2"-#1:T)IPL$I;8@1-A)C@"7O6)0/
M;_W]Z+VCM9@[#W9@&C=0';1Y=5Q#5V. [JV_&=(]R%A_3 GG$F6-X@">,)9U
M_AT"L2(RXJ(++%H+,ANV\/UV[)VG/%):-] >M+?U0-91TUQ ?5=<E)3SA(Y=
MRR")!!RJ<VCQ($:?A+)9YM28S-<4/#7RPU*\@?\(NUQO%E#/<0+Z=UU=MF>H
M]MR5US/NI0[<4Q*TZ)Y(HHEX80VQ'*@24E,MQ[@IM3'XSE,?*[$;@ _:['J%
M-1B[.GQ;N#FZPYCY(!U1W2U0F31./5IWCRP8S:U+EMEA7NQ>N)V'NGWR-F <
M83_K$*74KCC"N>3J/W ]$R:8*+- @K0.%4'"F41I$I1REFE<?@]<]VX,N_-8
MAR=S ]Y!>U>GM>O^J_#D>N&K8B8R%H06.! E.:[A\-I@G-;$9<$RAL*2&[8,
MOA=NYW%NG[P-CWH,VI1:/1CVYBJ<N7(._0,*0F:)>H'FGOG^63]%C-*>=(\
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M*5?"S&!_7=#K.<,9A4H1P$)S00L+(T!CPD%"!8V(?@@IM+6>O<AGEM<C5F#
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M"6&WHEH^7U\^V3Z3K__2TLLG_P=02P,$%     @ Y#V168BA,K 2"   FSX
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MO)@^$!3#^_+JV>T7W4OW6^97S_X+4$L! A0#%     @ Y#V169_>Z^(P,
MPUX! !8              ( !     '!F92TQ,C$W,C R-'AE>&@Y.2YH=&U0
M2P$"% ,4    " #D/9%9+@4UL8H0  "/@P  $               @ %D,
M<&9E+3(P,C0Q,C$W+FAT;5!+ 0(4 Q0    ( .0]D5F1?W?-' ,  #H*   0
M              "  1Q!  !P9F4M,C R-#$R,3<N>'-D4$L! A0#%     @
MY#V16?PD:>UB"    #P  !0              ( !9D0  '!F92TR,#(T,3(Q
M-U]D968N>&UL4$L! A0#%     @ Y#V162>T'SR.#   .6L  !0
M     ( !^DP  '!F92TR,#(T,3(Q-U]L86(N>&UL4$L! A0#%     @ Y#V1
M68BA,K 2"   FSX  !0              ( !NED  '!F92TR,#(T,3(Q-U]P
<<F4N>&UL4$L%!@     &  8 A@$  /YA      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>pfe-20241217_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20241217"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pfe-20241217.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2024-12-17</startDate>
            <endDate>2024-12-17</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-17</startDate>
            <endDate>2024-12-17</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-17</startDate>
            <endDate>2024-12-17</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0000078003</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentType contextRef="c-1" id="f-2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-4">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityRegistrantName contextRef="c-1" id="f-5">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-7">1-3619</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">66 Hudson Boulevard East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">10001-2192</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NY</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="c-1" id="f-13">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">733-2323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-19">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-20">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-21">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-22">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-23">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-24">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
